Janssen: Response to TB CAB letter
Janssen's response to TB CAB letter regarding pharmacokinetic studies, paediatric studies, and compassionate use of bedaquiline.
By Janssen Pharmaceutical Companies of Johnson & Johnson
Published: June 12, 2012, 8:36 p.m.
Last updated: June 13, 2012, 10:22 a.m.
